California State Teachers Retirement System Raises Stock Position in Kymera Therapeutics, Inc. $KYMRMarket Beat·Sep 14 at 07:22 AMKYMR-6.57%
KYMR: Oral immunology therapies targeting STAT6 and IRF5 advance toward key data readouts this yearQuartr·Sep 10 at 04:52 PMKYMR-6.57%
Maze Therapeutics Chief Executive Officer Sold Shares Worth Over $593KTradingView·Sep 4 at 08:30 PMMAZE-2.55%
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Position in Kymera Therapeutics, Inc. $KYMRMarket Beat·Sep 3 at 08:58 AMKYMR-6.57%
Kymera Therapeutics to join September investor conference fireside chats and presentationsPUBT·Sep 2 at 08:01 PMKYMR-6.57%C-0.02%
Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology CongressesUnusual Whales·Sep 1 at 11:01 AMKYMR-6.57%
The Biotech Boom's Hidden Catch: Progress and Peril in 2026Global Report·Aug 20 at 09:43 AMEDIT-5.99%KYMR-6.57%
Biotech Startups Shift Focus to Near-Term Milestones to Conserve CapitalGlobal Report·Aug 20 at 09:41 AMEDIT-5.99%KYMR-6.57%
California State Teachers Retirement System Increases Stake in Kymera Therapeutics, Inc. $KYMRMarket Beat·Aug 8 at 07:44 AMKYMR-6.57%
Kymera Therapeutics (KYMR) Stock Faces A Revenue Durability ReckoningSimplywall·Aug 6 at 09:56 AMKYMR-6.57%
Key facts: Kymera (KYMR) Q2 $65M; $1.5B cash; KT-621 data end-2026TradingView·Aug 6 at 07:15 AMKYMR-6.57%SNY-2.46%
Kymera Therapeutics (NASDAQ:KYMR) Releases Earnings Results, Beats Estimates By $0.09 EPSMarket Beat·Aug 5 at 06:41 PMKYMR-6.57%
